Levobupivacaine

Levobupivacaine, the active ingredient in Levobupivacaine, is a local anesthetic presented as a strength/form for intravenous use. It provides regional or local anesthesia for surgical procedures and postoperative pain management in adult patients.

GNH USA supplies Levobupivacaine as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Levobupivacaine is used in the management of pain and sensory blockade across several clinical settings. - Local anesthesia: produces reversible loss of sensation for minor surgical or diagnostic procedures. - Regional anesthesia: enables nerve block techniques for limb or trunk surgeries. - Postoperative analgesia: extends pain relief after surgery, reducing the need for systemic opioids.

Levobupivacaine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Hypotension: transient drop in blood pressure. - Bradycardia: slowed heart rate. - Dizziness or light‑headedness. - Metallic taste in the mouth. - Nausea or vomiting. - Transient visual disturbances.

Serious or Rare Side Effects: - Cardiac arrest or severe arrhythmias. - Seizures or central nervous system toxicity. - Prolonged motor block or nerve injury. - Allergic reactions including rash, bronchospasm, or anaphylaxis. - Methemoglobinemia. - Persistent cardiovascular collapse.

When using Levobupivacaine, clinicians should observe several safety measures. - Allergy assessment: avoid in patients with known hypersensitivity to amide‑type local anesthetics. - Cardiovascular monitoring: watch for arrhythmias, hypotension, or bradycardia during and after administration. - Dose adjustment: consider reduced doses in elderly patients or those with hepatic impairment. - Concomitant CNS depressants: use with caution as they may enhance neurotoxicity. - Pregnancy and lactation: administer only if the potential benefit justifies the potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levobupivacaine can interact with other medicines, altering its safety profile.

Major Interactions (Avoid): - Class I antiarrhythmic agents (e.g., quinidine, procainamide): may increase cardiotoxicity. - Beta‑blockers: can potentiate bradycardia and hypotension. - General anesthetics (e.g., sevoflurane, isoflurane): may enhance central nervous system depression.

Moderate Interactions (Monitor Closely): - Opioids: additive analgesic effect; monitor respiratory status. - NSAIDs: may increase bleeding risk when combined with regional blocks. - Magnesium sulfate: can potentiate neuromuscular blockade, requiring careful monitoring.